The Indiana Biosciences Research Institute in Indianapolis has detailed a partnership with four Hoosier colleges. The IBRI says the memorandum of understanding involves streamlining the way in which university technologies are licensed by removing hurdles and speeding up commercialization. Ball State University, Indiana University, Purdue University, and the University of Notre Dame have all signed on.
The IBRI says the formal collaboration will bolster its mission of strengthening ties between industry and academia. Incoming Chief Executive Officer Rainer Fischer, who was named CEO David Broecker’s successor last week, says the MOU helps the IBRI "unlock the value of discoveries being made at the state’s top research universities by further developing them or combining them with other technologies and bringing treatments to patients and innovations quicker to market."
Mass spectrometry and high-sensitivity technologies from Purdue and microfluidic technology from Notre Dame are the first licensees under the new arrangement with the IBRI. The IU School of Medicine and IBRI are already collaborating on cardio metabolic disease research. The MOU marks the first partnership between Ball State and the IBRI.
You can connect to more about the partnerships by clicking here.